CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO Annual Meeting.
Asciminib (Scemblix, Novartis) also exhibited a favorable safety and tolerability profile compared with imatinib and other tyrosine kinase inhibitors, researchers reported.
“CML is a chronic condition and, [although] TKIs have transformed the treatment landscape, many newly diagnosed patients fail to meet molecular response goals and many discontinue or change treatment due